Zeneca

AstraZeneca buying drug developer Alexion for $39 billion

Pharmaceutical company AstraZeneca says it is buying U.S. drug developer Alexion in a deal worth $39 billion.

Cambridge, England-based AstraZeneca PLC, which is involved in one of the efforts to develop a COVID-19 vaccine, said on Dec. 12 it's using a combination of cash and shares for the acquisition of Boston-based Alexion Pharmaceuticals Inc.